Systemic inflammation in patients with end-stage renal disease (ESRD) receiving different types of renal replacement therapy
-
1
Institute of Immunology and Physiology of Ural Branch of Russian Academy of Sciences, Russia
-
2
Sverdlovsk Regional Hospital №1, Russia
Objective. To assess the degree of chronic SI (CSI) in patients with ESRD receiving different types of renal replacement therapy.
The study included the following groups: patients with ESRD receiving program hemodialysis (12 hours per week, blood samples were taken prior to dialysis session (n=42), renal transplant patients with normal allograft function (n=23), patients with chronic allograft dysfunction (CAD, n=24). The control group included 50 healthy people. Chronic glomerulonephritis was the condition that resulted in the development of ESRD in all the patients. Blood plasma was tested for the following SI indicators: CRP, IL-6, IL-8, IL-10, TNFα, D-dimers, cortisol, myoglobin, troponin I. On the basis of these markers using an original method we calculated the integral index of intensity of chronic SI (from 0 to 8 points).
Results. CSI was diagnosed only in hemodialysis patients (90.9%) and in the CAD group (43.5%). The incidence of systemic inflammation reaction and tissue alteration was the highest (90.9% and 90.9%) in hemodialysis patients. Patients in the CAD group most often presented systemic inflammation reaction (91.3%) and distress of neuroendocrine system (56.5%). While elevated levels of proinflammatory cytokines and CRP (41.7%), distress of neuroendocrine system (29.2%), and microthrombosis (4.2%) were recorded in the normal allograft function group, on the whole, there were no cases of CSI.
Conclusion. CSI is a severe ESRD complication in hemodialysis patients. Following the renal transplantation CSI is found only in patients with CAD, proving that CSI is an additional link in the CAD pathogenesis.
Keywords:
chronic systemic inflammation,
end-stage renal disease,
chronic renal allograft dysfunction,
hemodialysis,
Inflammatory marker
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Innate immunity
Citation:
Zhuravleva
I,
Solomatina
L,
Panshina
E and
Gusev
E
(2013). Systemic inflammation in patients with end-stage renal disease (ESRD) receiving different types of renal replacement therapy.
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00375
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
26 Mar 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Mrs. Iuliia Zhuravleva, Institute of Immunology and Physiology of Ural Branch of Russian Academy of Sciences, Ekaterinburg, Russia, jazhur@mail.ru